Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
XMT - 1536 Has a New Name 6 upifitamab rilsodotin or UpRi, for short
Upifitamab Rilsodotin Under Investigation in Several Trials to Bridge ...
Upifitamab rilsodotin | CAS#:2254119-00-9 | Chemsrc
Journey Ends for Upifitamab Rilsodotin in NaPi2b+ Platinum-Resistant ...
Upifitamab Rilsodotin May Answer Questions in Platinum-Resistant ...
Upifitamab Rilsodotin Has Potential to Address Unmet Need in Recurrent ...
Upifitamab Rilsodotin - Drug Targets, Indications, Patents - Synapse
Dr Richardson on the UPLIFT Trial of Upifitamab Rilsodotin in Ovarian ...
Upifitamab Rilsodotin Fails to Meet ORR End Point in NaPi2b+ Platinum ...
Upifitamab Rilsodotin Misses Primary End Point in Ovarian Cancer ...
UPGRADE-A Trial of Upifitamab Rilsodotin in Ovarian Cancer Begins ...
Frontiers | Antibody-drug conjugates: the paradigm shifts in the ...
BD Biosciences DNA Reagent Kit (RUO/GMP) 1 Kit: Buffer (3 x 50 mL ...
美国APExBIO中文官网 - Anti-TIGIT Antibody (Vibostolimab)
Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON ...
Upifitamab (XMT-1535) | NaPi2b Monoclonal Antibody | MedChemExpress
Single-domain antibodies neutralize ricin toxin intracellularly by ...
Mersana下一代ADC技术平台 - 药时代DrugTimes
UP-NEXT study tests ovarian cancer treatment | EurekAlert!
Bispecific Antibodies and Antibody–Drug Conjugates in Relapsed ...
Immune-stimulating antibody conjugates elicit robust myeloid activation ...
Antibody–Drug Conjugates: The Last Decade
An Overview of the Development and Preclinical Evaluation of Antibody ...
Delivery of Drugs into Cancer Cells Using Antibody–Drug Conjugates ...
新靶点新类型药物深入探索，有望突破PROC治疗卵巢癌困局 - 企业动态 - 丁香通
Empowering Targeted Therapy: Lessons from Rituximab | Science's STKE
NOD2 Pathway Activation by MDP or Mycobacterium tuberculosis Infection ...
Frontiers | Induction of Potent and Durable Neutralizing Antibodies ...
Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of ...
The Rab Interacting Lysosomal Protein (RILP) Homology Domain Functions ...
A Collection of Single-Domain Antibodies that Crowd Ricin Toxin’s ...
Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody–Drug ...
Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell ...
Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent
RhsP2 Protein as a New Antibacterial Toxin Targeting RNA
Antibody-Drug Conjugates: Functional Principles and Applications in ...
Discovery of Synergistic Broadly Neutralizing Antibodies Targeting Non ...
Riluzole–Rasagiline Hybrids: Toward the Development of Multi-Target ...
Respiratory syncytial virus (RSV)-approved monoclonal antibody ...
Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas
Buy Mersana Therapeutics Stock - MRSN Stock Price Today & News - Public.com
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant ...
新靶点新类型药物深入探索，有望突破PROC治疗卵巢癌困局 - 知乎
尤匹菲妥单抗(Upifitamab Rilsodotin) - 药物靶点：NaPi-2b x Tubulin_在研适应症：转移性非小细胞肺癌 ...
SGO 2023 Phase 3 UP-NEXT Trial: Upifitamab Rilsodotin, a NaPi2b ...
ADC前"撤"之鉴(一): Upifitamab Rilsodotin、Enapotamab Vedotin_Payload_毒性_肿瘤
ABLi Therapeutics Reports Final Results from the Phase 2 ‘201 Trial ...
大道不孤——中国ADC创新药最新研发进展 前言 ADC， Antibody-drug Conjugate 的英文缩写，中文名称是 抗体偶联药物 ...
前“撤”可鉴(一)-Upifitamab Rilsodotin、Enapotamab Vedotin - 知乎
Intracellular Neutralization of Ricin Toxin by Single Domain Antibodies ...
Chemical structures of (a) riluzole and (b) levodopa b a | Download ...
Therapeutic antibodies and fusion inhibitors targeting the spike ...
Monoclonal Antibodies | ReceptaBio | São Paulo
Humanized Monoclonal Antibody That Passively Protects Mice against ...
Rebmab200, a Humanized Monoclonal Antibody Targeting the Sodium ...
RI-002, an intravenous immunoglobulin containing high titer ...
抗体药物偶联物(ADC)和泛偶联物(XDC)在卵巢癌中的临床证据汇总(2025.3) - 知乎
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy ...
Zymeworks：CD3/MSLN双抗明年IND，NaPi-2b ADC后年IND医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
潜在首创ADC再失利，Mersana裁员50%、砍管线求生医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
14.6亿美元！GSK押注一款新型HER2 ADC医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
八次跨膜蛋白NaPi2b—肺癌与卵巢癌治疗的种子选手？-公司新闻-苏州近岸蛋白质科技股份有限公司
2023Q3失败临床研究TOP22医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
5例患者死亡，NaPi-2b ADC两项临床研究被FDA部分暂停医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
FiercePharma：2021年最具竞争力 ADC 企业Top 10医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Novel Radioimmunotherapy Reverses Resistance | EurekAlert!
股价大跌60%，是灾难还是机会？医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
